Archive - March 2025
FDA Approves Bomyntra (denosumab-bnht), a Biosimilar to Xgeva
FDA Approves Conexxence (denosumab-bnht), a Biosimilar to Prolia
Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
Biorasi: Director, Business Development
Enzyme engineering opens door to novel therapies for Parkinson's, cancers and other hard-to-target protein diseases
FDA Approves Vykat XR (diazoxide choline) to Treat Hyperphagia in Prader-Willi Syndrome
FDA Approves Blujepa (gepotidacin) for the Treatment of Uncomplicated Urinary Tract Infections
UK Biocentre: Director, Business Development